Pharmacoepidemiology

863 publications in "Pharmacoepidemiology"

Oct-14

Descriptive Study of Exposure to Inhalation Zanamivir and Pregnancy-Related Outcomes

Gynecology and Obstetrics Paediatrics Pharmacoepidemiology Women's Health

Read more

Oct-14

Discontinuation of antipsychotic medication in pregnancy: a cohort study

Gynecology and Obstetrics Pharmacoepidemiology Women's Health

Read more

Oct-14

Impact of methodological choices on findings from pharmacoepidemiological studies: Final results of the IMI-protect (pharmacoepidemiological research on outcomes of therapeutics by a European consortium) project

Pharmacoepidemiology

Read more

Oct-14

Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study

Cardiovascular Pharmacoepidemiology

Read more

Oct-14

Myocardial Infarction Risk with Diclofenac Use in Spondyloarthropathy Versus Non-Inflammatory Low Back Pain

Cardiovascular Pharmacoepidemiology Rheumatology

Read more

Oct-14

Prescription of antihypertensive medications during pregnancy in the UK

Gynecology and Obstetrics Pharmacoepidemiology Women's Health

Read more

Oct-14

Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis

Pharmacoepidemiology Smoking

Read more

Sep-14

Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network

Dermatology Pharmacoepidemiology Rheumatology

Read more

Sep-14

Serum uric acid and the risk of respiratory disease: a population-based cohort study

Pharmacoepidemiology Respiratory

Read more

Sep-14

Incidence and predictors of haemorrhagic stroke in a cohort of patients receiving acetylsalicylic acid for secondary prevention of cardiovascular events

Cardiovascular Neurology Pharmacoepidemiology

Read more

Sep-14

Predictors of glycaemic response to add-on therapy with a DPP-IV inhibitor: a retrospective cohort study using the primary care THIN database

Endocrinology Pharmacoepidemiology

Read more

Sep-14

The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK

Endocrinology Healthcare Cost Pharmacoepidemiology

Read more
Date Title Categories
Oct-14 Descriptive Study of Exposure to Inhalation Zanamivir and Pregnancy-Related Outcomes

Gynecology and Obstetrics Paediatrics Pharmacoepidemiology Women's Health

Oct-14 Discontinuation of antipsychotic medication in pregnancy: a cohort study

Gynecology and Obstetrics Pharmacoepidemiology Women's Health

Oct-14 Impact of methodological choices on findings from pharmacoepidemiological studies: Final results of the IMI-protect (pharmacoepidemiological research on outcomes of therapeutics by a European consortium) project

Pharmacoepidemiology

Oct-14 Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study

Cardiovascular Pharmacoepidemiology

Oct-14 Myocardial Infarction Risk with Diclofenac Use in Spondyloarthropathy Versus Non-Inflammatory Low Back Pain

Cardiovascular Pharmacoepidemiology Rheumatology

Oct-14 Prescription of antihypertensive medications during pregnancy in the UK

Gynecology and Obstetrics Pharmacoepidemiology Women's Health

Oct-14 Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis

Pharmacoepidemiology Smoking

Sep-14 Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network

Dermatology Pharmacoepidemiology Rheumatology

Sep-14 Serum uric acid and the risk of respiratory disease: a population-based cohort study

Pharmacoepidemiology Respiratory

Sep-14 Incidence and predictors of haemorrhagic stroke in a cohort of patients receiving acetylsalicylic acid for secondary prevention of cardiovascular events

Cardiovascular Neurology Pharmacoepidemiology

Sep-14 Predictors of glycaemic response to add-on therapy with a DPP-IV inhibitor: a retrospective cohort study using the primary care THIN database

Endocrinology Pharmacoepidemiology

Sep-14 The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK

Endocrinology Healthcare Cost Pharmacoepidemiology

1 41 42 43 44 45 72